SetupAI
EN
來源較早收集於 59m

PI3Kα 抑制劑在罕見疾病治療的突破

閱讀原文： 钛媒体
#biotech#drug-discovery

了解計算生物學與 AI 如何加速複雜罕見疾病的藥物開發。

30 秒速覽

有什麼變化

PI3Kα 抑制劑療效的提升

為什麼重要

這項研究可能帶動利用 AI 驅動分子建模的新藥開發管線。它凸顯了計算生物學與藥物開發的交叉應用。

下一步行動

若您從事生物技術領域，請嘗試使用 AlphaFold 3 來模擬新型 PI3Kα 抑制劑候選藥物的結合親和力。

誰應關注：Researchers & Academics

關鍵要點

  • •PI3Kα 抑制劑療效的提升
  • •針對特定罕見疾病路徑
  • •新型治療應用的潛力

深度解析

背景與延伸：來自公開資料，非原文內容。引用 30 個來源。

增強重點摘要

  • •The development of PI3Kα inhibitors is increasingly focusing on mutant-selective approaches to mitigate common side effects like hyperglycemia, which has been a significant challenge with earlier, less selective inhibitors.
  • •Beyond oncology, PI3Kα inhibitors are demonstrating efficacy in treating rare genetic overgrowth syndromes and vascular anomalies, such as PIK3CA-related overgrowth spectrum (PROS) and Activated PI3K-delta Syndrome (APDS), driven by specific PIK3CA mutations.
  • •The PI3K/AKT/mTOR signaling pathway, in which PI3Kα plays a crucial role, is frequently hyperactivated in various cancers and rare diseases due to somatic or germline mutations in genes like PIK3CA, PTEN, PIK3CD, and PIK3R1.
  • •Recent clinical trials, such as Relay Therapeutics' Phase 2 ReInspire trial for zovegalisib in PIK3CA-driven vascular anomalies, have shown robust volumetric responses and symptomatic improvements, supporting the potential for mutant-selective PI3Kα inhibition in these underserved populations.
  • •The pharmaceutical industry has been actively pursuing PI3K inhibitors since the 1980s, with the first PI3K inhibitor (idelalisib) receiving FDA approval in 2014, highlighting a long-standing effort to therapeutically target this pathway.

競品分析

Mechanism
Alpelisib (Novartis)
Selective PI3Kα inhibitor (mutant + wild-type)
Inavolisib (Roche/Genentech)
Highly potent & selective PI3Kα inhibitor
Zovegalisib (Relay Therapeutics)
Allosteric, mutant-selective PI3Kα inhibitor
Tersolisib (Eli Lilly, acquired from Scorpion)
Mutant-selective PI3Kα inhibitor
Key Indications
Alpelisib (Novartis)
HR+/HER2- Breast Cancer (PIK3CA mutation), PROS
Inavolisib (Roche/Genentech)
1L HR+/HER2- MBC, PIK3CA-mutant
Zovegalisib (Relay Therapeutics)
Phase 3: HR+/HER2- Breast Cancer; Phase 2: Vascular Anomalies (PIK3CA-driven)
Tersolisib (Eli Lilly, acquired from Scorpion)
Phase 3: 1L HR+/HER2- MBC, PIK3CA-mutant
Approval/Status
Alpelisib (Novartis)
Approved (2019 for breast cancer, 2022 for PROS)
Inavolisib (Roche/Genentech)
Approved (2024 for breast cancer)
Zovegalisib (Relay Therapeutics)
Phase 3 (Breast Cancer), Phase 2 (Vascular Anomalies)
Tersolisib (Eli Lilly, acquired from Scorpion)
Phase 3 (Breast Cancer)
Notable Side Effects
Alpelisib (Novartis)
Significant hyperglycemia (~37% Grade 3/4), rash, diarrhea, stomatitis
Inavolisib (Roche/Genentech)
Metabolic & GI side effects, neutropenia, stomatitis, hyperglycemia, diarrhea, rash
Zovegalisib (Relay Therapeutics)
Aims for reduced toxicity; lower rates of hyperglycemia, stomatitis, rash compared to non-mutant-selective inhibitors
Tersolisib (Eli Lilly, acquired from Scorpion)
Designed to spare wild-type PI3Kα to reduce toxicity
Key Benchmarks
Alpelisib (Novartis)
PFS +5.3 months vs placebo (SOLAR-1 trial)
Inavolisib (Roche/Genentech)
PFS +7.7 months vs placebo (15.0 vs 7.3 months)
Zovegalisib (Relay Therapeutics)
60% volumetric response in vascular anomalies (Phase 2); 11.1 months mPFS in breast cancer (Phase 1)
Tersolisib (Eli Lilly, acquired from Scorpion)
No clinical results released yet for Phase 3

技術深入

  • Mechanism of Action: PI3Kα inhibitors function by binding to the ATP-binding pocket of the PI3Kα enzyme, thereby preventing its interaction with ATP, which is essential for its kinase activity. This inhibition leads to a decrease in phosphatidylinositol (3,4,5)-trisphosphate (PIP3) levels, suppressing Akt activation and subsequently inhibiting downstream signaling pathways like mTOR, ultimately leading to reduced cell proliferation and induction of apoptosis.
  • Isoform Selectivity: A critical technical challenge in PI3K inhibitor development is achieving high selectivity for the alpha isoform (PI3Kα) over other Class I PI3K isoforms (β, γ, δ) and wild-type PI3Kα. This selectivity is crucial to minimize off-target effects, particularly hyperglycemia, which is often associated with the inhibition of wild-type PI3Kα involved in insulin signaling.
  • Allosteric vs. Catalytic Inhibition: While many PI3Kα inhibitors are catalytic, binding directly to the active site, newer approaches include allosteric inhibitors. Allosteric inhibitors, such as Relay Therapeutics' zovegalisib and Loxo Oncology's LOXO-783, bind to a site distinct from the active site, inducing a conformational change that inactivates the enzyme. This mechanism can offer enhanced selectivity and a potentially improved safety profile.
  • Key Genetic Mutations: PI3Kα inhibitors primarily target activating mutations in the PIK3CA gene, which encodes the p110α catalytic subunit of PI3K. Common hotspot mutations include E542K and E545K in the helical domain, and H1047L and H1047R in the kinase domain, which lead to constitutive activation of the PI3K pathway.
  • Adverse Event Management: Due to the ubiquitous role of PI3Kα in cellular processes, common side effects include hyperglycemia, rash, diarrhea, nausea, and stomatitis. Strategies to manage hyperglycemia often involve close monitoring of blood glucose levels and, in some cases, co-administration of medications like metformin.

前景展望基於引用來源的 AI 分析

Mutant-selective PI3Kα inhibitors will become the preferred therapeutic option for PIK3CA-mutated rare diseases and cancers.
Their improved safety profiles, particularly reduced incidence of hyperglycemia, combined with demonstrated efficacy in clinical trials, position them to replace less selective inhibitors.
The use of PI3Kα inhibitors in combination therapies will significantly expand, particularly in oncology.
PI3K pathway activation often contributes to resistance to other cancer treatments, and combining PI3Kα inhibitors with other targeted agents (e.g., CDK4/6 inhibitors, endocrine therapy) has shown enhanced and more durable efficacy.
Routine genetic screening for PIK3CA mutations will become standard practice for a broader spectrum of rare diseases.
The success of PI3Kα inhibitors in treating PIK3CA-related overgrowth spectrum (PROS) and vascular anomalies underscores the critical need to identify these specific genetic drivers for effective targeted therapeutic intervention.

時間線

1980s
Identification of PI3K and its emergence as a therapeutic target.
2004
Discovery of *PIK3CA* gene faults in human cancer, linking specific mutations to PI3K pathway activation.
2014
First FDA approval of a PI3K inhibitor, idelalisib (PI3Kδ-selective), for certain B-cell malignancies.
2019
FDA approval of alpelisib (Novartis), the first PI3Kα-selective inhibitor, for *PIK3CA*-mutated HR+/HER2- breast cancer.
2022-2023
Expansion of PI3K inhibitor indications into rare diseases with FDA approvals for alpelisib (Vijoice) in PROS (2022) and leniolisib in APDS (2023).
2026-05
Relay Therapeutics announces positive Phase 2 data for zovegalisib, a mutant-selective PI3Kα inhibitor, in PIK3CA-driven vascular anomalies.
閱讀原文： 钛媒体

AI 週報

閱讀本週精選 AI 大事摘要 →

PostLinkedIn

AI 策展新聞聚合。所有內容版權歸原始發布者所有。
原始來源： 钛媒体 ↗

這是摘要，不是原文。去看原站，或訂閱每週簡報。

每週電子報

每週一封，可隨時退訂。